Roche’s Crenezumab Creeps Forward But Has All To Play For In Phase III Trials
Phase II data for Roche’s Alzheimer’s disease MAb, crenezumab, has upheld its proposed mechanism of action but competitor aducanumab still has the upper hand with evidence of disease-modifying potential.
You may also be interested in...
Interim top-line data from CREAD 1 and 2 indicate crenezeumab is unlikely to meet its primary endpoints and the studies are being stopped, but a clinical study in Colombia in familial Alzheimer’s is set to continue.
Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.
The failure of BACE inhibitor lanabecestat was the latest setback in Lilly's Alzheimer's pipeline, but the company has been working in this area with almost no success for decades, yet still feels a commitment to keep trying, Lilly Research Labs President Daniel Skovronsky tells Scrip.